Impact of body composition parameters on clinical outcomes in patients with metastatic castrate-resistant prostate cancer treated with docetaxel.

摘要: Summary Background Body composition may influence clinical outcomes of certain chemotherapeutic agents. We examined the prognostic significance skeletal muscle mass and adipose tissue on docetaxel toxicity overall survival in patients with metastatic castrate resistant prostate cancer (mCRPC). Methods A retrospective review medical records mCRPC, treated was conducted. parameters (skeletal mass, attenuation [MA], visceral subcutaneous tissue) were measured at L3 by computed tomography (CT) defined using previously established cut points. Toxicity profile assessed after 3 cycles drug graded according to National Cancer Institute Common Criteria (version 4). Overall analysed. Results 63 patients, mean age 69 years (SD 8.3), included. Sarcopenia present 47% (n = 30) these 26.7% (8/30) sarcopenic obese. toxicities (all grades) observed included fatigue (80.9%), pain (46%), constipation (34.9%). DLT occurred 22 (34.9%) patients; 10 (15.8%) experienced dose reductions 12 (19%) terminations. Measurements adiposity not predictive DLT, however 59.1% who had a combination both sarcopenia low MA compared 29.3% without (p = 0.021). Skeletal index significantly lower neutropenia (grade I–II) (46.5 cm 2 /m vs. 51.2 cm , p = 0.005) their counterparts (24.6 HU 32.2 HU, p = 0.044). Neither nor obesity associated survival. In multivariate analysis, BMI ≥25 kg/m (HR: 0.349, CI: 0.156–0.782, p = 0.010) significant predictor longer fat index ≥ median 58.7 cm 2.266 1.066–4.814, p = 0.033) anaemia 2.81, 1.297–6.091, p = 0.009) predictors shorter Conclusions are I–II). Furthermore, presence anaemia, high volume reduced being chemotherapy.